Edap (EDAP +3.4%) gains after saying the FDA has given the thumbs-up on a pre-market approval application for its Ablatherm Integrated Imaging HIFU device, a high-intensity utrasound treatment for low-risk, localized prostate cancer.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs